On May 5, 2016, the Canadian Agency for Drugs and Technologies in Health (CADTH) released a Recommendations Report on its project on Anti-Vascular Endothelial Growth Factor (VEGF) Drugs for Retinal Conditions.

CADTH has undertaken a therapeutic review comparing the clinical effectiveness and relative cost of three anti-VEGF drugs (aflibercept, bevacizumab, ranibizumab) that are commonly used to treat the following retinal conditions: age-related macular degeneration (AMD), choroidal neovascularisation (CNV), diabetic macular edema (DME), pathologic myopia (PM), and retinal vein occlusion (RVO). The therapeutic review project includes a science report (clinical and economic evaluations) and a recommendations report.

For a copy of the above-mentioned reports, please click on the following link.